In PNAS this week: diversity and spread of Yersinia pestis, local adaptations in switchgrass, and more.
The acquisition will result in a new DLS division called HudsonAlpha Discovery that will provide a range of services to the pharma, biotech, and diagnostics industries.
HudsonAlpha's Genome Gateway collects family histories and facilitates secure communication between patients, clinicians, and researchers.
PyxisMap, unveiled at the recent ISMB conference, might soon be able to remove the human element from finding causal variants for rare diseases.
The funding will help support the whole-genome and RNA sequencing of Alzheimer's disease patients to advance biomarker development.
CFDRC obtained iXG's high-throughput antimicrobial discovery platform, EMAD (extremophilic microbiome antimicrobial discovery).
The project seeks to understand how genome sequencing as a first-line diagnostic in infants with likely hereditary disorders can impact long-term health outcomes.
HudsonAlpha researchers analyzed the genomes of parents whose children were in a study of developmental delay and intellectual disability for secondary findings.
Speakers at HudsonAlpha's Genomic Medicine Conference said while sequencing results sometimes result in a diagnosis and change in care, they often have no consequence.
The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.
Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.
Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.
In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.